Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers

Respiratory Medicine

Volumn 97, Issue SUPPL. 2, 2003, Pages

  Poli, G ^a   Acerbi, D ^a  

^a CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

Asthma; Beclometasone dipropionate; Bioavailability; Cortisol suppression; Metered dose inhaler; Nebulized drugs; Suspension for nebulization

Indexed keywords

BECLOMETASONE 17 MONOPROPIONATE; BECLOMETASONE DIPROPIONATE; DRUG METABOLITE; HYDROCORTISONE; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; BECLOMETASONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MEAN RESIDENCE TIME; METERED DOSE INHALER; NEBULIZATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; URINARY EXCRETION; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HALF LIFE TIME; INHALATIONAL DRUG ADMINISTRATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; URINE;

ADMINISTRATION, INHALATION; ADULT; ANTI-ASTHMATIC AGENTS; BECLOMETHASONE; BIOLOGICAL AVAILABILITY; HALF-LIFE; HUMANS; HYDROCORTISONE; MALE; METERED DOSE INHALERS;

EID: 0037316055     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(03)90071-0     Document Type: Article

References (10)

1. Würthwein G, Rohdewald P. Activation of beclometasone dipropionate by hydrolysis to beclometasone-17-monopropionate. Biopharm Drug Dis 1990; 11: 381-394.
2. Miller-Larson A, Mattsson H, Hjertberg E, et al. Reversible fatty acid conjugation of budesonide. Mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Disp 1998; 26(7): 623-630.
3. Pelizzi N, Catinella S, Puccini P, et al. LC/MS demonstration of the in vitro fatty acid ester formation from antiasthmatic glucocorticoids. 20th Informal Meeting on Mass Spectrometry, 12-16 May, 2002, Italy.
4. Terzano C, Mannino F. Aerosol caratteristiche, analisi, applicazioni terapeutiche. McGraw-Hill, 1997.
5. Kendrick AH, Smith EC, Wilson RSE. Selecting and using nebulizer equipment. Thorax 1997; 52(Suppl 2): S92-101.
6. Berglund E. Inhalation therapy: Problems and prospects. Eur Respir J 1990; 3: 830.
7. Pedersen S, Frost L, Arufred T. Errors in inhalation technique and efficacy in inhaler use in asthmatic children. Allergy 1986; 41: 118.
8. Wales D, Makker H, Kane J, et al. Systemic bioavailability and potency of high-dose inhaled corticosteroids. A comparison of four inhaler devices and three drugs in healthy adult volunteers. Chest 1999; 115: 1278-1284.
9. Bisgaard H, Nikander K, Munch E. Comparative study of budesonide as a nebulized suspension vs pressurized metered-dose inhaler in adult asthmatics. Respir Med 1998; 92: 44-49.
10. O'Callaghan C, Barry P. Delivering inhaled corticosteroids to patients. BMJ 1999; 8: 410-411.